Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men aged 18 or older who are currently being monitored through an Active Surveillance clinic for prostate cancer.
- Men who have been diagnosed with prostate cancer and whose medical team has agreed at a specialist group meeting that Active Surveillance (monitoring rather than immediate treatment) is the right approach.
- Men from any background who have a family history of prostate cancer, such as a close male relative diagnosed before age 70, two relatives on the same side of the family with at least one diagnosed before 70, or three relatives on the same side of the family diagnosed at any age.
- Men of Black African or Black African-Caribbean ancestry, where both parents and all four grandparents are from that background.
- Men from any background who carry a gene change (mutation) known to increase prostate cancer risk, such as in the BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, or CHEK2 genes, among others (confirm with trial site for full gene list).
- Men from any background whose genetic testing shows a combined risk score of at least twice the average risk of developing prostate cancer.
- Men from any background with no known high genetic risk factors who have been diagnosed with low-grade prostate cancer and assessed as suitable for Active Surveillance at a specialist group meeting (these participants form a comparison group).
- Men who are generally well enough to carry out daily activities with little or no limitation (performance status 0–2, confirm with trial site).
- Men who have no psychological, family, social, or location-related circumstances that would make it difficult to follow the study plan and attend follow-up appointments.
Who may not be able to join:
- Men who have not been diagnosed with prostate cancer.
- Men whose prostate cancer has been assessed at a specialist group meeting as not suitable for Active Surveillance.
- Men with significant psychological conditions that could be made worse by taking part in the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ros A Eeles, FRCP, FRFR, Institute of Cancer Research and Royal Marsden Hospital
Phone: 02087224483
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To determine the incidence of disease progression of PrCa in the cohorts studied.; To determine the incidence of aggressiveness of PrCa in the cohorts studied.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.